Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Viramune

Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12

Nevirapine concentrations not measured, no effect is expected. INTEGRASE INHIBITORS Elvitegravir/cobicistat Interaction has not been studied. Coadministration of Viramune Cobicistat, a cytochrome P450 3A with elvitegravir in combination inhibitor significantly inhibits with cobicistat is not recommended hepatic enzymes, as well as other (see section 4.4). metabolic pathways. Therefore coadministration would likely result in altered plasma levels of cobicistat and Viramune. Raltegravir No clinical data available. Due to Raltegravir and Viramune can be 400 mg BID the metabolic pathway of co-administered without dose raltegravir no interaction is adjustments. expected. ANTIBIOTICS Clarithromycin Clarithromycin AUC  0.69 Clarithromycin exposure was 500 mg BID (0.62-0.76) significantly decreased, 14-OH Clarithromycin Cmin  0.44 metabolite exposure increased. (0.30-0.64) Because the clarithromycin active Clarithromycin Cmax  0.77 metabolite has reduced activity (0.69-0.86) against Mycobacterium avium- intracellulare complex overall Metabolite 14-OH clarithromycin activity against the pathogen may AUC  1.42 (1.16-1.73) be altered. Alternatives to Metabolite 14-OH clarithromycin clarithromycin, such as Cmin  0 (0.68-1.49) azithromycin should be considered. Metabolite 14-OH clarithromycin Close monitoring for hepatic Cmax  1.47 (1.21-1.80) abnormalities is recommended

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cobicistat (HOS-088111) azithromycin (HOS-088112) clarithromycin (HOS-084517) raltegravir (HOS-086187) elvitegravir (HOS-088110)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage cf7f3bf4c95b2388228c494f913a21a4dc6fc418bee30f18d985d5b4c96318ce · Zeichen 12414–14588 im Abschnitt

Wechselwirkungen · Viramune

Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 37

HOS-088209 · Präparat HOS-083615

Raltegravir No clinical data available. Due to Raltegravir and Viramune can be 400 mg BID the metabolic pathway of co-administered without dose raltegravir no interaction is adjustments. expected. ANTIBIOTICS Clarithromycin Clarithromycin AUC  0.69 Clarithromycin exposure was 500 mg BID (0.62-0.76) significantly decreased, 14-OH Clarithromycin Cmin  0.44 metabolite exposure increased. (0.30-0.64) Because the clarithromycin active Clarithromycin Cmax  0.77 metabolite has reduced activity (0.69-0.86) against Mycobacterium avium- intracellulare complex overall Metabolite 14-OH clarithromycin activity against the pathogen may AUC  1.42 (1.16-1.73) be altered. Alternatives to Metabolite 14-OH clarithromycin clarithromycin, such as Cmin  0 (0.68-1.49) azithromycin should be considered. Metabolite 14-OH clarithromycin Close monitoring for hepatic Cmax  1.47 (1.21-1.80) abnormalities is recommended

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112) clarithromycin (HOS-084517) raltegravir (HOS-086187)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage a4b52c14a20634e861dda601de718619991cf118c18e1a4befb823bc554f9e6b · Zeichen 13267–14672 im Abschnitt

Wechselwirkungen · Viramune

Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 62

HOS-088301 · Präparat HOS-083615

Raltegravir No clinical data available. Due to Raltegravir and Viramune can be 400 mg BID the metabolic pathway of co-administered without dose raltegravir no interaction is adjustments. expected. ANTIBIOTICS Clarithromycin Clarithromycin AUC  0.69 Clarithromycin exposure was 500 mg BID (0.62-0.76) significantly decreased, 14-OH Clarithromycin Cmin  0.44 metabolite exposure increased. (0.30-0.64) Because the clarithromycin active Clarithromycin Cmax  0.77 metabolite has reduced activity (0.69-0.86) against Mycobacterium avium- intracellulare complex overall Metabolite 14-OH clarithromycin activity against the pathogen may AUC  1.42 (1.16-1.73) be altered. Alternatives to Metabolite 14-OH clarithromycin clarithromycin, such as Cmin  0 (0.68-1.49) azithromycin should be considered. Metabolite 14-OH clarithromycin Close monitoring for hepatic Cmax  1.47 (1.21-1.80) abnormalities is recommended

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112) clarithromycin (HOS-084517) raltegravir (HOS-086187)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 576e0e48a042c2cc49eb62bbdc4d9ead770bba33c905227e72718e8576d86182 · Zeichen 13367–14823 im Abschnitt

Wechselwirkungen · Viagra

VIAGRA 25 mg film-coated tablets VIAGRA 50 mg film-coated tablets VIAGRA 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-088785 · Präparat HOS-083727

When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily. for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite. Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) azithromycin (HOS-088112) erythromycin (HOS-084514)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage b1a7510326328ceb33f9ef26d0946952dc0c0bf901aadb8f1327143bc9b44f80 · Zeichen 1998–2669 im Abschnitt

Wechselwirkungen · Viagra

VIAGRA 50 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 20

HOS-088846 · Präparat HOS-083727

When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite. Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) azithromycin (HOS-088112) erythromycin (HOS-084514)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage af0bf6ded38ff0767d107642a9116c14aa01848c1cd8bef75028af2e9f96ad84 · Zeichen 2056–2726 im Abschnitt

Wechselwirkungen · Viagra

VIAGRA 50 mg orodispersible films · Abschnitt 4.5 · PDF-Seite 34

HOS-088896 · Präparat HOS-083727

When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite. Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) azithromycin (HOS-088112) erythromycin (HOS-084514)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage af0bf6ded38ff0767d107642a9116c14aa01848c1cd8bef75028af2e9f96ad84 · Zeichen 2054–2724 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 25–26

HOS-108940 · Präparat HOS-093083

Methadone Methadone: ↓ Monitoring plasma concentrations of methadone is recommended. Oral contraceptives Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of Kaletra with contraceptives containing ethinyl oestradiol (whatever the contraceptive formulation e.g. oral or patch), additional methods of contraception must be used. Smoking cessation aids Bupropion Buproprion and its active If the co-administration of Kaletra metabolite, hydroxybupropion: with bupropion is judged AUC and Cmax ↓ ~50% unavoidable, this should be done under close clinical monitoring for This effect may be due to bupropion efficacy, without induction of bupropion exceeding the recommended metabolism. dosage, despite the observed induction. Thyroid hormone replacement therapy Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone reported indicating a potential (TSH) should be monitored in interaction between ritonavir patients treated with levothyroxine containing products and at least the first month after levothyroxine. starting and/or ending lopinavir/ritonavir treatment. Vasodilating agents 25 Bosentan Lopinavir - ritonavir: Caution should be exercised in Lopinavir/ritonavir plasma administering Kaletra with concentrations may decrease due bosentan. to CYP3A4 induction by When Kaletra is administered bosentan. concomitantly with bosentan, the efficacy of the HIV therapy should Bosentan: be monitored and patients should AUC: ↑ 5-fold be closely observed for bosentan Cmax: ↑ 6-fold toxicity, especially during the first Initially, bosentan Cmin: ↑ by week of co-administration. approximately 48-fold. Due to CYP3A4 inhibition by lopinavir/ritonavir. Riociguat Serum concentrations may be The co-administration of riociguat increased due to CYP3A and with Kaletra is not recommended P-gp inhibition by (see section 4.4 and refer to lopinavir/ritonavir. riociguat SmPC). Other medicinal products Based on known metabolic profiles, clinically significant interactions are not expected between Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) methadone (HOS-086198) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8d752c4274572732732b0956ff6ff26c5cf23921c5ef2d225aedad5e185afa6d · Zeichen 59817–63890 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61

HOS-109024 · Präparat HOS-093083

Thyroid hormone replacement therapy Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone (TSH) reported indicating a potential should be monitored in patients interaction between ritonavir treated with levothyroxine at least the containing products and first month after starting and/or levothyroxine. ending lopinavir/ritonavir treatment. Vasodilating agents Bosentan Lopinavir - ritonavir: Caution should be exercised in Lopinavir/ritonavir plasma administering Kaletra with bosentan. concentrations may decrease due When Kaletra is administered to CYP3A4 induction by concomitantly with bosentan, the bosentan. efficacy of the HIV therapy should be monitored and patients should be Bosentan: closely observed for bosentan AUC: ↑ 5-fold toxicity, especially during the first Cmax: ↑ 6-fold week of co-administration. Initially, bosentan Cmin: ↑ by approximately 48-fold. Due to CYP3A4 inhibition by lopinavir/ritonavir. Riociguat Serum concentrations may be The co-administration of riociguat increased due to CYP3A and P-gp with Kaletra is not recommended inhibition by lopinavir/ritonavir. (see section 4.4 and refer to riociguat SmPC). Other medicinal products Based on known metabolic profiles, clinically significant interactions are not expected between Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) riociguat (HOS-086293) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 65f5a6f4d7302840533b08e744ce8d52c7c6cce98bf349aa71cfb302b25446dd · Zeichen 59068–61276 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 96–97

HOS-109102 · Präparat HOS-093083

96 Oral contraceptives Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of Kaletra with contraceptives containing ethinyl oestradiol (whatever the contraceptive formulation e.g. oral or patch), additional methods of contraception must be used. Smoking cessation aids Bupropion Buproprion and its active If the co-administration of Kaletra metabolite, hydroxybupropion: with bupropion is judged AUC and Cmax ↓ ~50% unavoidable, this should be done under close clinical monitoring for This effect may be due to bupropion efficacy, without induction of bupropion exceeding the recommended metabolism. dosage, despite the observed induction. Thyroid hormone replacement therapy Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone reported indicating a potential (TSH) should be monitored in interaction between ritonavir patients treated with levothyroxine containing products and at least the first month after starting levothyroxine. and/or ending lopinavir/ritonavir treatment. Vasodilating agents Bosentan Lopinavir - ritonavir: Caution should be exercised in Lopinavir/ritonavir plasma administering Kaletra with concentrations may decrease due bosentan. to CYP3A4 induction by When Kaletra is administered bosentan. concomitantly with bosentan, the efficacy of the HIV therapy should Bosentan: be monitored and patients should be AUC: ↑ 5-fold closely observed for bosentan Cmax: ↑ 6-fold toxicity, especially during the first Initially, bosentan Cmin: ↑ by week of coadministration. approximately 48-fold. Due to CYP3A4 inhibition by lopinavir/ritonavir. Riociguat Serum concentrations may be The co-administration of riociguat increased due to CYP3A and with Kaletra is not recommended P-gp inhibition by (see section 4.4 and refer to lopinavir/ritonavir. riociguat SmPC). Other medicinal products Based on known metabolic profiles, clinically significant interactions are not expected between Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage eb717f7573e257a0db9660c2692fa6be3f81b8ac5b4c1043b1f49219b74ffa31 · Zeichen 58967–62731 im Abschnitt

Wechselwirkungen · Vfend

VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11

HOS-109444 · Präparat HOS-093201

Azithromycin (500 mg QD) Voriconazole Cmax and AUC ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage de05711df6afdb3e1932dbdd2ce289878d590b7852bea1fbea0db7fb74dbc2e2 · Zeichen 4874–4930 im Abschnitt

Wechselwirkungen · Vfend

VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12

HOS-109445 · Präparat HOS-093201

Erythromycin (1 g BID) Voriconazole Cmax and AUC ↔ [CYP3A4 inhibitor] The effect of voriconazole on either erythromycin or azithromycin is unknown. Rifabutin Concomitant use of voriconazole [potent CYP450 inducer] and rifabutin should be avoided Voriconazole Cmax  69% unless the benefit outweighs the 300 mg QD Voriconazole AUC  78% risk. The maintenance dose of Compared to voriconazole 200 mg voriconazole may be increased to 300 mg QD (coadministered BID, 5 mg/kg intravenously BID or with voriconazole 350 mg Voriconazole Cmax  4% from 200 mg to 350 mg orally BID)* Voriconazole AUC  32% BID (100 mg to 200 mg orally BID in patients less than 40 kg) (see section 4.2). Careful monitoring of full blood Rifabutin Cmax  195% counts and adverse reactions to 300 mg QD (coadministered Rifabutin AUC  331% rifabutin (e.g., uveitis) is with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is BID)* BID, coadministered with voriconazole. Voriconazole Cmax  104% Voriconazole AUC  87% Rifampicin (600 mg QD) Voriconazole Cmax  93% Contraindicated (see section [potent CYP450 inducer] Voriconazole AUC  96% 4.3) Anti-cancer agents Glasdegib Although not studied, voriconazole If concomitant use cannot be [CYP3A4 substrate] is likely to increase the plasma avoided, frequent ECG concentrations of glasdegib and monitoring is recommended (see increase risk of QTc prolongation. section 4.4). Tretinoin Although not studied, voriconazole Dose adjustment of tretinoin is [CYP3A4 substrate] may increase tretinoin recommended during treatment concentrations and increase risk of with voriconazole and after its adverse reactions (pseudotumor discontinuation. cerebri, hypercalcaemia). 11 Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be (including but not limited to: may increase plasma avoided, dose reduction of the axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is cobimetinib, dabrafenib, recommended (see section 4.4). dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) [CYP3A4 substrates] Venetoclax Although not studied, voriconazole Concomitant administration of [CYP3A substrate] is likely to significantly increase voriconazole is contraindicated the plasma concentrations of at initiation and during venetoclax. venetoclax dose titration phase (see section 4.3). Dose reduction of venetoclax is required as instructed in venetoclax prescribing information during steady daily dosing; close monitoring for signs of toxicity is recommended. Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids not limited to: vincristine and is likely to increase the plasma should be considered. vinblastine) concentrations of vinca alkaloids [CYP3A4 substrates] and lead to neurotoxicity. Anticoagulants Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin coadministered with 300 mg time was approximately 2-fold. time or other suitable BID voriconazole) anticoagulation tests is [CYP2C9 substrate] recommended, and the dose of anticoagulants should be adjusted Other oral coumarins Although not studied, voriconazole accordingly. (including but not limited to: may increase the plasma phenprocoumon, concentrations of coumarins that acenocoumarol) may cause an increase in [CYP2C9 and CYP3A4 prothrombin time. substrates] Anticonvulsants Carbamazepine and Although not studied, Contraindicated (see section long-acting barbiturates carbamazepine and long-acting 4.3) (including but not limited to: barbiturates are likely to phenobarbital, mephobarbital) significantly decrease plasma [potent CYP450 inducers] voriconazole concentrations. Phenytoin Concomitant use of voriconazole [CYP2C9 substrate and potent and phenytoin should be avoided CYP450 inducer] unless the benefit outweighs the risk. Careful monitoring of 300 mg QD Voriconazole Cmax  49% phenytoin plasma levels is Voriconazole AUC  69% recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) vinblastine (HOS-086220) glasdegib (HOS-109446) vincristine (HOS-086219) azithromycin (HOS-088112) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) tretinoin (HOS-109447) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) erythromycin (HOS-084514) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 92969ff5c9d1e7ffb4a2f7eaf265abd9d2899e7061ac52ea8adefc4d660b4316 · Zeichen 4932–11582 im Abschnitt

Wechselwirkungen · Vfend

VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 42

HOS-109535 · Präparat HOS-093201

Azithromycin (500 mg QD) Voriconazole Cmax and AUC ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 71a65319941effa2356f3bbdf650d66f29d7594a37f2e3e57b3df80195881959 · Zeichen 4969–5031 im Abschnitt

Wechselwirkungen · Vfend

VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 42

HOS-109536 · Präparat HOS-093201

Erythromycin (1 g BID) Voriconazole Cmax and AUC ↔ [CYP3A4 inhibitor] The effect of voriconazole on either erythromycin or azithromycin is unknown.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112) erythromycin (HOS-084514)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 82c771c8cd1609645711d540236021812d7c040d195a497c2a329363c7d5204f · Zeichen 5033–5294 im Abschnitt

Wechselwirkungen · Vfend

VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 75

HOS-109600 · Präparat HOS-093201

Azithromycin (500 mg QD) Voriconazole Cmax and AUC ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage de05711df6afdb3e1932dbdd2ce289878d590b7852bea1fbea0db7fb74dbc2e2 · Zeichen 4890–4946 im Abschnitt

Wechselwirkungen · Vfend

VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 75

HOS-109601 · Präparat HOS-093201

Erythromycin (1 g BID) Voriconazole Cmax and AUC ↔ [CYP3A4 inhibitor] The effect of voriconazole on either erythromycin or azithromycin is unknown. Rifabutin Concomitant use of voriconazole [potent CYP450 inducer] and rifabutin should be avoided Voriconazole Cmax  69% unless the benefit outweighs the 300 mg QD Voriconazole AUC  78% risk. The maintenance dose of Compared to voriconazole 200 mg voriconazole may be increased to 300 mg QD (coadministered BID, 5 mg/kg intravenously BID or with voriconazole 350 mg Voriconazole Cmax  4% from 200 mg to 350 mg orally BID)* Voriconazole AUC  32% BID (100 mg to 200 mg orally BID in patients less than 40 kg) (see section 4.2). Careful monitoring of full blood Rifabutin Cmax  195% counts and adverse reactions to 300 mg QD (coadministered Rifabutin AUC  331% rifabutin (e.g., uveitis) is with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is BID)* BID, coadministered with voriconazole. Voriconazole Cmax  104% Voriconazole AUC  87%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) azithromycin (HOS-088112) erythromycin (HOS-084514)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 70d2842c89a0f76b2b89010da68a228ee91da2104f8948deb891ed4d807cbace · Zeichen 4948–6767 im Abschnitt

Wechselwirkungen · Revatio

Revatio 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-114936 · Präparat HOS-094193

When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182 % increase in sildenafil systemic exposure (AUC). For dose recommendations, see section 4.2. In healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, Tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite. No dose adjustment is required. Cimetidine (800 mg), a cytochrome P450 inhibitor and a non-specific CYP3A4 inhibitor, caused a 56 % increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers. No dose adjustment is required.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) azithromycin (HOS-088112) erythromycin (HOS-084514)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage d240fc2a890a7da09f21477b5256b6627cbd3ac5aca700b44b068578e8f11f05 · Zeichen 4191–4965 im Abschnitt

Wechselwirkungen · Revatio

Revatio 0.8 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 27

HOS-114999 · Präparat HOS-094193

When a single 100 mg dose of oral sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182 % increase in sildenafil systemic exposure (AUC). For dose recommendations, see section 4.2. In healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, Tmax, elimination rate constant, or subsequent half-life of oral sildenafil or its principal circulating metabolite. No dose adjustment is required. Cimetidine (800 mg), a cytochrome P450 inhibitor and a non-specific CYP3A4 inhibitor, caused a 56 % increase in plasma sildenafil concentrations when co-administered with oral sildenafil (50 mg) to healthy volunteers. No dose adjustment is required.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) azithromycin (HOS-088112) erythromycin (HOS-084514)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 41616a2f0dfdf85c08795faa0e68a234bfd62555b2de352339ebe9342c0ea2d3 · Zeichen 4924–5713 im Abschnitt

Wechselwirkungen · Revatio

Revatio 10 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 45

HOS-115057 · Präparat HOS-094193

When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182 % increase in sildenafil systemic exposure (AUC). For dose recommendations, see section 4.2. In healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, Tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite. No dose adjustment is required. Cimetidine (800 mg), a cytochrome P450 inhibitor and a non-specific CYP3A4 inhibitor, caused a 56 % increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers. No dose adjustment is required.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) azithromycin (HOS-088112) erythromycin (HOS-084514)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage d240fc2a890a7da09f21477b5256b6627cbd3ac5aca700b44b068578e8f11f05 · Zeichen 4192–4966 im Abschnitt

Wechselwirkungen · Advagraf

Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11

HOS-116802 · Präparat HOS-094481

10 Drug/Substance Class or Drug interaction effect Recommendations concerning Name co-administration Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that antifungal agents (e.g., blood trough concentrations and concomitant use should be ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider (e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus troleandomycin, [see section 4.4]. the day the strong CYP3A4 clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a (e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on saquinavir), HCV protease administration, despite immediate tacrolimus blood inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be and paritaprevir with combinations are co-administered, individualized and adjusted as ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which nefazodone, the require a reduction in tacrolimus should be assessed at initiation, pharmacokinetic enhancer dose and temporary interruption of monitored frequently cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the inhibitors idelalisib, The effect on tacrolimus blood first few days) and re- ceritinib. concentrations may remain for evaluated on and after Strong interactions have also several days after co-administration completion of the CYP3A4 been observed with the is completed. inhibitor. Upon completion, macrolide antibiotic appropriate dose and dosing erythromycin frequency of tacrolimus should be guided by tacrolimus blood concentrations. Monitor renal function, ECG for QT prolongation, and other side effects closely. Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole inhibitors: blood trough concentrations and blood trough concentrations antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co- clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see (e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal channel blockers (e.g., function, ECG for QT nifedipine, nicardipine, prolongation, and other side diltiazem, verapamil), effects closely. amiodarone, danazol, ethinylestradiol, lansoprazole, omeprazole, the HCV antivirals elbasvir/grazoprevir and glecaprevir/pibrentasvir, the CMV antiviral letermovir, and the tyrosine kinase inhibitors nilotinib, crizotinib and imatinib and (Chinese) herbal remedies containing extracts of Schisandra sphenanthera

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt

Wechselwirkungen · Intelence

INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-119738 · Präparat HOS-095005

9 Integrase Strand Transfer Inhibitors Dolutegravir dolutegravir Etravirine significantly 50 mg once daily AUC ↓ 0.29 (0.26-0.34) reduced plasma Cmin ↓ 0.12 (0.09-0.16) concentrations of Cmax ↓ 0.48 (0.43-0.54) dolutegravir. The effect of etravirine etravirine on dolutegravir AUC ↔a plasma concentrations was Cmin ↔a mitigated by Cmax ↔a co-administration of darunavir/ritonavir or Dolutegravir + dolutegravir lopinavir/ritonavir, and is darunavir/ritonavir AUC↓ 0.75 (0.69-0.81) expected to be mitigated by 50 mg once daily + Cmin ↓ 0.63 (0.52-0.77) atazanavir/ritonavir. 600/100 mg twice daily Cmax ↓ 0.88 (0.78-1.00) etravirine INTELENCE should only be AUC ↔a used with dolutegravir when Cmin ↔a co-administered with Cmax ↔a atazanavir/ritonavir, darunavir/ritonavir, or Dolutegravir + dolutegravir lopinavir/ritonavir. This Lopinavir/ritonavir AUC↔ 1.11(1.02-1.20) combination can be used 50 mg once daily + Cmin ↑ 1.28 (1.13-1.45) without dose adjustment. 400/100 mg twice daily Cmax ↔ 1.07 (1.02-1.13) etravirine AUC ↔a Cmin ↔a Cmax ↔a Raltegravir raltegravir INTELENCE and raltegravir 400 mg twice daily AUC ↓ 0.90 (0.68-1.18) can be used without dose Cmin ↓ 0.66 (0.34-1.26) adjustments. Cmax ↓ 0.89 (0.68-1.15) etravirine AUC ↔ 1.10 (1.03-1.16) Cmin ↔ 1.17 (1.10-1.26) Cmax ↔ 1.04 (0.97-1.12) ANTIARRHYTHMICS Digoxin digoxin INTELENCE and digoxin 0.5 mg single dose AUC ↑ 1.18 (0.90-1.56) can be used without dose Cmin ND adjustments. It is Cmax ↑ 1.19 (0.96-1.49) recommended that digoxin levels be monitored when digoxin is combined with INTELENCE. Amiodarone Not studied. INTELENCE is expected to Caution is warranted and Bepridil decrease plasma concentrations of these therapeutic concentration Disopyramide antiarrhythmics. monitoring, if available, is Flecainide recommended for Lidocaine (systemic) antiarrhythmics when Mexiletine co-administered with Propafenone INTELENCE. Quinidine ANTIBIOTICS Azithromycin Not studied. Based on the biliary elimination INTELENCE and pathway of azithromycin, no drug interactions azithromycin can be used are expected between azithromycin and without dose adjustments. INTELENCE.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) propafenone (HOS-084530) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) bepridil (HOS-085612) dolutegravir (HOS-089992) quinidine (HOS-085593) digoxin (HOS-086172) azithromycin (HOS-088112) disopyramide (HOS-085595) darunavir (HOS-086181) raltegravir (HOS-086187) ritonavir (HOS-084521) amiodarone (HOS-085596)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage 88eab8e7a4aadd0b0d68eee60d8b6c66c61e5724eefbfde8ea7e2649457e571e · Zeichen 11566–16118 im Abschnitt

Quellenpassagen (52)

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Viagra

Wechselwirkungen · Viagra

Wechselwirkungen · Viagra

Wechselwirkungen · Kaletra

Wechselwirkungen · Kaletra

Wechselwirkungen · Kaletra

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Revatio

Wechselwirkungen · Revatio

Wechselwirkungen · Revatio

Wechselwirkungen · Advagraf

Wechselwirkungen · Intelence